Mark Freedman (Ottawa Hospital and Ottawa Hospital Research Institute), a recent welcome addition to our editorial board for US Neurology, considers treatment biomarkers in multiple sclerosis including discussion around his presentation on neurofilament light chain (NF-L) levels before and after bone marrow transplant (abstract available here: n.neurology.org/content/90/15_..., and the clinical relevance of NEDA (no evidence of disease activity).
Questions
1. You have a presentation on neurofilament light chain (NF-L) levels before and after bone marrow transplant. What did this study reveal about the use of serum NF-L as a potential biomarker for response to therapy? (0:11)
2. Is NEDA (no evidence of disease activity) the new target for treatment in multiple sclerosis (MS)? (1:35)
3. On the basis of current evidence, what do you consider to be the optimal treatment regimen for MS? (3:23)
Speaker disclosures: Mark Freedman has received honoraria or consultation fees from Bayer Healthcare, Biogen-Idec, Chugai, EMD Canada, Genzyme, Novartis, Sanofi-Aventis and Teva Canada Innovation. He is a member of the following company advisory boards, board of directors or other similar group for Bayer Healthcare, Biogen-Idec, Hoffman La-Roche, Merck Serono, Novartis, Opexa and Sanofi-Aventis. He is a participant in Genzyme’s company-sponsored speaker’s bureau.
Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018.